Abstract 570P
Background
Mismatch repair deficient or microsatellite instable (MSI) tumors are often characterized by high mutational burdens and strong immune infiltration and have shown higher sensitivity to immune checkpoint inhibitors (ICIs) compared to microsatellite stable (MSS) tumors. However, only a portion of the patients with MSI colorectal cancer (CRC) gain survival benefits from ICIs treatment, suggesting unclear heterogeneity in MSI tumors.
Methods
We analyzed the whole-genomes and transcriptomes of 223 ICIs treatment-naïve MSI CRC tumors from U-CAN project. Immune cell infiltration and cancer-relevant pathways were evaluated by CIBERSORT and PROGENy, respectively. An MSI subtyping model was developed based on ResNet50.
Results
Unsupervised classification based on gene expression data divided MSI tumors into two distinct classes (class1 and 2), with MSI class1 characterized by a lower level of chromosomal instability, a higher level of hypoxia, and more activated EGFR, JAK-STAT, TNFa, and NFkB pathways than class2. However, two MSI classes showed no differences in 5-year survival. Further investigation of the immune cell population showed that class1 had considerably higher immune cell infiltration compared to class2, specifically in M0, M1 and M2 macrophages, CD4 and CD8 T-cells, naïve B-cells, resting NK-cells, and neutrophiles. Class2 exhibited significantly higher loss in 10q23.31 (containing PTEN) and reduced expression of PTEN, which may lead to an immunosuppressive tumor microenvironment and partially explain the higher activation in PI3K and VEGF pathways in class2 compared to class1. Importantly, ICIs targets, such as CTLA4, PD-1, and PD-L1 all had higher expressions in calss1. We further developed an MSI subtyping model based on refined pathway features of normal tissue, tumors with MSS, class1 or 2. Ongoing analyses include validation of MSI classification in the TCGA dataset.
Conclusions
We illustrated the heterogeneity in MSI CRCs and revealed two subclasses of MSI with distinct molecular features, which may be informative for immune-based treatments. The MSI subtyping model may further facilitate precision immunotherapy and allow patients to derive clinical benefits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University Umeå University BGI-Shenzhen.
Funding
The Swedish Cancer Society the Uppsala Cancer Foundation the Guangdong Provincial Key Laboratory of Human Disease Genomics the Swedish Government (CancerUU) the Erling-Persson Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
518P - Artificial intelligence real-world applications in pediatric neuro-oncology: The AICCELERATE project
Presenter: Federica D'Antonio
Session: Poster session 10
519P - The landscape of PDGFRA mutation in Chinese patients with glioma
Presenter: Qiang Lv
Session: Poster session 10
520P - Copy number variation spectrum analysis of primary glioblastoma
Presenter: Chuandong Cheng
Session: Poster session 10
521P - Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS
Presenter: Ana Belen Diaz Mendez
Session: Poster session 10
522P - Galectin 3 binding protein as potential biomarker in glioma diagnosis
Presenter: Rashmi Rana
Session: Poster session 10
523P - Analysis of DNA damage response (DDR) gene expression as a prognostic factor for glioblastoma patient mortality
Presenter: Alessia-Tara Droesse
Session: Poster session 10
524P - Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma
Presenter: Jonathan Decarpentrie
Session: Poster session 10
525P - Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery
Presenter: Lorena Gurrieri
Session: Poster session 10
526P - In silico evaluation of the mutational profile of glioblastomas with high expression of PD1, CTLA4 and LAG3 identifies the ERBB-PI3K pathway as a druggable vulnerability target
Presenter: Cristina Saiz-Ladera
Session: Poster session 10
527P - Targetable gene fusions and other alterations in central nervous system tumors assessed by RNA and DNA-based next-generation sequencing
Presenter: LEIMING WANG
Session: Poster session 10